Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
Minoo Mohraz(Iranian Institute for Health Sciences Research), Hamed Hosseini(Tehran University of Medical Sciences), Payam Tabarsi(Masih Daneshvari Hospital), Yasaman Ghabdian(Tehran University of Medical Sciences), Mohsen Abbasi‐Kangevari(Tehran University of Medical Sciences), Asghar Abdoli(Shahid Beheshti University), Sahar Saeedi Moghaddam(Kiel Institute for the World Economy), Farzin Khorvash(Isfahan University of Medical Sciences), Seyyed‐Hadi Ghamari(Shahid Beheshti University of Medical Sciences), Mohammadreza Salehi(Tehran University of Medical Sciences), Mohsen Moghadami(Shiraz University of Medical Sciences), Mohammad‐Reza Malekpour(Tehran University of Medical Sciences), Rozita Khodashahi(Mashhad University of Medical Sciences), Katayoun Vahdat(Office of Infectious Diseases), Keyvan Koohgir(Shahroud University of Medical Sciences), Maryam Amini Pouya(Isfahan University of Medical Sciences), Erfan Ghasemi(Tehran University of Medical Sciences), Negar Rezaei(Tehran University of Medical Sciences)
Cited by 17
Related Papers
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2020|19.7k
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2020|9.8k
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet Neurology|2021|7.9k